Strand Therapeutics Raises $153M in Series B

Strand Therapeutics has successfully raised $153M in a Series B led by Kinnevik, Regeneron Ventures, ICONIQ, Amgen Ventures.

Company Overview

Strand Therapeutics is a HealthTech company headquartered in Cambridge, MA, founded in 2019 with 80+ employees.

Programmable mRNA therapeutics for cancer treatment

Fundraising Details

• Amount Raised: $153M
• Round Type: Series B
• Date: 2025-08-07
• Investors: Kinnevik, Regeneron Ventures, ICONIQ, Amgen Ventures

About Strand Therapeutics

Programmable mRNA therapeutics for cancer treatment The company is positioned in the HealthTech sector, serving a growing market with innovative solutions.

Key Information

• Headquarters: Cambridge, MA
• Founded: 2019
• Team Size: 80+
• Industry: HealthTech

What This Means

This funding round demonstrates strong investor confidence in Strand Therapeutics's vision and execution. The capital will likely be used to:

• Scale Operations: Expand the team and operational capacity
• Product Development: Enhance existing products and develop new features
• Market Expansion: Enter new markets and strengthen presence in existing ones
• Technology Investment: Invest in infrastructure and technology capabilities

Industry Context

The HealthTech sector continues to attract significant investment as companies innovate to meet evolving market demands. Strand Therapeutics's successful fundraising reflects the strong fundamentals and growth potential in this space.

Looking Ahead

With this new capital, Strand Therapeutics is well-positioned to execute on its growth strategy and continue building innovative solutions in the HealthTech space. The company's trajectory will be one to watch as it deploys this funding to achieve its next phase of growth.

This fundraising news was reported on 2025-08-07. For more information about Strand Therapeutics, visit their headquarters at Cambridge, MA.